Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein cysteine thiols are the reactive sulfhydryl (-SH) groups located on the side chains of cysteine residues within proteins. These groups are essential for maintaining the three-dimensional structure of proteins through disulfide bond formation and serve as critical nucleophiles in the catalytic sites of various enzymes, such as proteases and phosphatases (Go & Jones, 2013). Beyond structural and catalytic roles, cysteine thiols act as molecular switches in redox signaling; they can undergo reversible post-translational modifications like S-nitrosylation and S-glutathionylation in response to oxidative or nitrosative stress (Hess et al., 2005). In many diseases, including cancer and neurodegeneration, the redox state of these thiols is disrupted, leading to protein dysfunction or aggregation (Halliwell & Gutteridge, 2015). Pharmacologically, these thiols are targeted by electrophilic drugs that covalently modify specific residues to modulate pathway activity, such as the activation of the Nrf2 antioxidant response by dimethyl fumarate (Linker et al., 2011). Additionally, many modern kinase inhibitors are designed to form covalent bonds with non-catalytic cysteine thiols to achieve high potency and selectivity (Barf & Kaptein, 2012). Their unique reactivity makes them central to both cellular homeostasis and the development of targeted covalent therapeutics.
Drugs interact with protein cysteine thiols primarily through covalent modification, where electrophilic molecules react with the nucleophilic sulfur atom to form a stable adduct (Barf & Kaptein, 2012). This interaction can result in the irreversible inhibition of enzymes, the activation of cytoprotective transcription factors like Nrf2 via the modification of Keap1 thiols, or the restoration of cellular redox balance by providing reducing equivalents or acting as a precursor to glutathione (Linker et al., 2011; Samuni et al., 2013).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Cysteine Thiol (P-SH).